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Abstract
Purpose To provide insight into the current use and results
of ultrasound-facilitated catheter-directed thrombolysis
(USAT) in patients with high-risk pulmonary embolism
(PE).
Introduction Systemic thrombolysis is an effective treat-
ment for hemodynamically unstable, high-risk PE, but is
associated with bleeding complications. USAT is thought
to reduce bleeding and is therefore advocated in patients
with high-risk PE and contraindications for systemic
thrombolysis.
Methods We conducted a retrospective cohort study of all
patients who underwent USAT for high-risk PE in the
Netherlands from 2010 to 2017. Characteristics and out-
comes were analyzed. Primary outcomes were major
(including intracranial and fatal) bleeding and all-cause
mortality after 1 month. Secondary outcomes were all-
cause mortality and recurrent venous thromboembolism
within 3 months.
Results 33 patients underwent USAT for high-risk PE.
Major bleeding occurred in 12 patients (36%, 95% CI
22–53), including 1 intracranial and 3 fatal bleeding. All-
cause mortality after 1 month was 48% (16/33, 95% CI
31–66). All-cause mortality after 3 months was 50% (16/
32, 95% CI 34–66), recurrent venous thromboembolism
occurred in 1 patient (1/32, 3%, 95% CI 1–16).
Conclusions This study was the first to describe charac-
teristics and outcomes after USAT in a study population of
patients with high-risk PE only, an understudied popula-
tion. Although USAT is considered a relatively safe
treatment option, our results illustrate that at least caution
is needed in critically ill patients with high-risk PE. Further
research in patients with high-risk PE is warranted to guide
patient selection.
Keywords Pulmonary embolism  Thrombolytic
therapy  Emergency treatment
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Introduction
Pulmonary embolism (PE) is a common cardiovascular
disease that can result in significant morbidity and death.
PE patients with hemodynamic shock or hypotension are
classified as high-risk, those with right ventricular (RV)
dysfunction and/or myocardial injury as intermediate-risk
and patients without those signs as low risk of mortality
[1]. In the high-risk group, comprising 5% of all PE
patients, an in-hospital mortality of 25–65% is found,
depending on clinical presentation and timely availability
of treatment [1–3]. Systemic thrombolysis (ST) is standard
of care in high-risk patients [1–4]. It has been shown to
restore pulmonary perfusion more rapidly compared to
standard anticoagulation alone, thereby improving RV
function and reducing mortality [5–8]. However, systemic
thrombolysis carries a 20% risk of major bleeding,
including a 2–3% risk of intracranial hemorrhage
[1, 4, 9, 10]. Consequently, risk factors for bleeding are
considered (relative) contraindications for this treatment
[8, 11]. Currently, in patients with high-risk PE in whom
ST is contraindicated or has failed, surgical embolectomy
or ultrasound-assisted catheter-directed thrombolysis
(USAT) is advised [1]. USAT, using the EkoSonic
Endovascular system (EKOS Corporation; Bothell, WA,
USA) is currently the most studied catheter-based tech-
nique using a lower dose of thrombolytic agent. With this
catheter, ultrasound is used to drive the thrombolytic agent
directly into plasminogen receptor sites within the throm-
bus and separate fibrin strands more efficiently [12, 13].
Previous studies on USAT and other local thrombolytic
interventions for PE did show a reduction of pulmonary
artery pressure and improved echocardiographic parame-
ters, with a favorable safety profile [14–27]. However,
these studies had a short follow-up and lacked clinically
relevant outcomes, such as major bleeding. More impor-
tantly, study populations were relatively small and
involved mainly intermediate-risk patients. Whereas most
evidence regarding efficacy and safety of USAT originates
from data on intermediate-risk patients, its main indication
is for high-risk PE. In previous literature, patients with
high-risk PE were either not or scarcely included. Ideally, a
randomized controlled trial comparing ST and USAT
would be undertaken to identify the best strategy for
patients with high-risk PE. However, these patients are by
definition hemodynamically unstable and often require
immediate life-saving therapy that cannot be postponed by
asking informed consent. Therefore, we need to assess the
effect of this strategy using data from case series and
registries. Currently, USAT is only advised in high-risk
patients in whom ST is contraindicated or has failed [1].
However, evidence supporting this strategy is scarce.
The aim of this retrospective study was to provide
insight into the use and outcomes of USAT in patients with
high-risk PE treated according to current guidelines.
Materials and Methods
Study Design and Setting
This retrospective cohort study was conducted at all hos-
pitals performing USAT in the Netherlands, including three
academic hospitals (University Medical Center Utrecht,
Utrecht, the Netherlands, Erasmus Medical Center, Rot-
terdam, the Netherlands and VU University Medical Cen-
ter, Amsterdam, the Netherlands) and one tertiary referral
center for cardiovascular and pulmonary disease (St.
Antonius hospital, Nieuwegein, the Netherlands).
Selection of Participants
We included all patients that underwent USAT for PE in
the Netherlands since its introduction in 2010 until July
2017. Patients were identified from a database maintained
by interventional cardiologists performing USAT, by
searching radiology reports on ‘thrombectomy, ‘fibrinoly-
sis’, ‘pulmonary arteries’, ‘thoracic arteries’ and ‘EKOS’
and by using software implemented in the local electronic
medical record. Demographic data and clinical information
were extracted from medical records.
Definitions
PE was, according to guidelines, diagnosed with computed
tomographic pulmonary angiography (CTPA) or, when
considered unsafe, a high clinical suspicion with or without
RV dysfunction on echocardiography [1]. High-risk PE
was defined as PE with hemodynamic shock or hypoten-
sion (systolic blood pressure\ 100 mmHg or a decline
of[ 40 mmHg) [1]. Shock is defined as hypotension or
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other signs of reduced tissue perfusion (altered mental
state, oliguria, clammy and pale skin, hyperlactatemia) [1].
Intermediate-risk PE was defined as PE with RV dys-
function and/or elevated cardiac biomarkers [1]. The
presence of RV dysfunction (dilated, enlarged or decom-
pensated right ventricle, right heart strain, RV failure or
dysfunction) was extracted from echocardiography and
CTPA reports. Bleeding risk factors are based on American
College of Chest Physicians and European Society of
Cardiology guidelines [1, 28]. Major bleeding risk factors
include recent hemorrhagic stroke, surgery, trauma, head
injury, gastrointestinal bleeding, central nervous system
malignancies and active bleeding. Minor bleeding risk
factors are recent transient ischemic attack, current thera-
peutic anticoagulation, pregnancy, traumatic resuscitation,
refractory hypertension, end stage liver disease, infectious
endocarditis and active stomach ulcer.
Intervention
According to guidelines, ST is administered in high-risk PE
patients without major contraindications (abovementioned
major risk factors) [1]. USAT is considered in patients with
high-risk PE and contraindications for ST whose condition
is otherwise stable enough to be transported to the
catheterization laboratory. Local practice varies regarding
combination with other therapies, including extracorporeal
membrane oxygenation (ECMO), thrombus aspiration and
ST.
USAT was performed by interventional cardiologists
(Utrecht) or radiologists (Nieuwegein, Rotterdam, Ams-
terdam). Venous access was obtained via the femoral or
internal jugular vein. The catheters are placed under fluo-
roscopic guidance according to CTPA images. Before
inserting the EKOS-catheters, a pulmonary angiogram was
performed. In case of bilateral PE, two EKOS-catheters
were placed through the thrombus in the pulmonary artery
under fluoroscopy, one on each side, and 12 mg of Alte-
plase was administered per catheter for 12 h. In case of
unilateral PE, one EKOS-catheter was placed, and 24 mg
of Alteplase was locally administered for 24 h. Echocar-
diography is frequently performed after catheter removal to
assess the effect of USAT on RV dysfunction. Moreover,
the patient’s clinical condition is monitored closely. In case
of insufficient clinical and echocardiographic improve-
ment, repeat CTPA is often performed to aid further clin-
ical decisions regarding additional therapies. Heparin was
administered according to predefined protocols. In one
hospital (Utrecht), an intravenous bolus of heparin of
5000 IE or 80 IE per kilogram body weight is administered
before USAT, and continuous infusion is started after
USAT with a target activated Partial Thromboplastin Time
(aPTT) of 2–2.5. In the other hospitals (Nieuwegein,
Rotterdam, Amsterdam) heparin is administered concomi-
tantly, based on a target level of 2.5–3, and continued
afterwards. If no bleeding had occurred within 24–48 h
after thrombolysis, standard anticoagulation therapy con-
sisting of direct oral anticoagulants (DOAC), low molec-
ular weight heparin (LMWH) or a vitamin K antagonist
(VKA) was started.
Outcome Assessment
Primary outcomes were all-cause mortality during the first
month of follow-up as well as major bleeding, including
intracranial hemorrhage and fatal bleeding, as defined by
the International Society on Thrombosis and Haemostasis
(ISTH) [28]. Secondary outcomes were all-cause mortality
and recurrent VTE after 3 months of follow-up, objectively
confirmed by CTPA, perfusion-scintigraphy, pulmonary
angiography, compression ultrasound or phlebography [1].
All outcomes were evaluated using clinical information as
noted in patient files.
Analysis
Baseline characteristics and outcomes are reported as per-
centages or median with interquartile range (IQR) as
variables were non-normally distributed. Patients treated
with USAT and other therapies or USAT only were com-
pared using two-sided Chi square and Fisher’s exact tests.
All statistical analyses were performed with SPSS version
21 (SPSS Inc., Chicago, Illinois, USA). p values\ 0.05
were considered significant.
Results
Characteristics of Study Subjects
We identified 35 patients with high-risk PE that underwent
treatment with USAT in the Netherlands (Fig. 1). Two
patients were lost to follow-up. Baseline characteristics are
shown in Table 1. Before proceeding to therapy, definitive
diagnosis was obtained by CTPA in 26/33, and by
echocardiography in 5/33 patients. In two patients, PE was
suspected on clinical grounds or high pulmonary artery
pressures during coronary angiography, and later con-
firmed by CTPA and pulmonary angiography, respectively.
USAT was performed bilaterally in 30/33 patients. Aver-
age dose of thrombolytic agent used during USAT in 25
patients treated with Alteplase was 26 mg (SD 11). Three
patients received a different thrombolytic agent. USAT was
discontinued earlier because of bleeding (n = 2) or in case
of death during treatment (n = 3). In these patients, average
dose of Alteplase is unknown.
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Outcomes
Table 2 shows primary and secondary outcomes. Twelve
patients (36%, 95% CI 22–53) suffered from major
bleeding, as specified in Table 3. Three patients died from
bleeding (3/33, 9%). One of these patients presented with
both high-risk PE and ischemic stroke, which was subject
to hemorrhagic transformation after USAT. Two other
patients with fatal bleeding both experienced traumatic
resuscitation resulting in multiple rib fractures and died
from hypovolemic shock after severe thoracic bleeding and
bleeding from access sites.
Thirteen patients (39%, 95% CI 25–56) died from cau-
ses other than bleeding, of whom four did not respond to
USAT and one died from recurrent PE. Irreversible brain
damage, organ failure, heparin-induced thrombocytopenia,
sepsis and glioblastoma led to the death of the other
patients. No other episodes of recurrent VTE were
observed.
USAT and Additional Therapies
Table 4 illustrates treatment and outcomes of fourteen
patients that received additional therapy. Thrombus aspi-
ration was performed concomitant with USAT in four
patients. In the other cases, when the initial treatment of
either ST or USAT led to insufficient improvement, other
strategies were opted for.
Of fourteen patients treated with USAT in combination
with ST or thrombus aspiration, four patients suffered from
major bleeding (29%, 95% CI 12–55), including one fatal.
In total, seven patients died (50%, 95% CI 27–73). Simi-
larly, in the group of patients treated with USAT only
(n = 19, of whom two with ECMO support), major
bleeding occurred in 42% (95% CI 23–64), whereas death
occurred in 47% (95% CI 27–28). A somewhat higher
mortality was seen in patients treated with both USAT and
ST (n = 10) compared to patients treated with USAT with
or without thrombus aspiration (n = 23) (70 vs. 39%,
p = 0.14). The incidence of major bleeding was similar
between those groups (30 vs. 39%, p = 0.71).
Discussion
The aim of this study was to provide insight into current
use and outcomes of USAT for high-risk PE in the
Netherlands. We observed a very high rate of major
bleeding and a high mortality rate. According to guidelines,
USAT is to be considered in patients with high-risk PE and
relative contraindications to ST. Our results indeed indicate
a critically ill high-risk population, reflecting a real-world
clinical setting. This case series adds important data on the
characteristics and outcomes of this understudied patient
population.
In our study population, major bleeding occurred in
36%, of which a quarter fatal. Several reasons can be
identified for this higher incidence compared to ± 10%
major bleeding in previous literature. Our study population
involved patients with high-risk PE only, as opposed to
Fig. 1 Flowchart of the
included patients. AZN St.
Antonius Hospital Nieuwegein,
EMC Erasmus Medical Center
Rotterdam, UMCU University
Medical Center Utrecht, USAT
ultrasound-facilitated, catheter-
directed local thrombolysis,
VUMC VU University Medical
Center Amsterdam
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12–22% with high-risk PE in other studies
[15, 16, 18, 19, 24, 25]. Furthermore, our findings are based
on real-world data and reflect how current guidelines are
put into practice. This means that our study population
involves a large proportion of patients with contraindica-
tions to ST (in particular recent surgery or traumatic
resuscitation) or whose condition did not improve despite
ST. Finally, a high percentage in our cohort had major
bleeding risk factors. All patients suffering from fatal
bleeding after USAT had at least one minor or major risk
factor. This restates that, especially in the presence of
major risk factors, USAT carries a serious risk of major
bleeding [4, 7].
A higher all-cause mortality was observed in our pop-
ulation compared to other studies [18, 19, 24, 25]. This
could, similarly, reflect our study population of high-risk
patients only, whose risk of death is almost ten times that
of those with intermediate-risk PE [1, 4]. However, a recent
meta-analysis on catheter-directed therapies for PE found
an all-cause mortality of 13% in a separately analyzed
group of 186 patients with massive (high-risk) PE [16].
This could be explained by differences in indication for
USAT and patient selection. Our population consisted of
those at highest risk among high-risk patients, a subgroup
presumably not included in previous literature. A higher
mortality was observed in patients who received USAT and
ST concurrently. The incidences of major and fatal
bleeding were similar, which may be explained by severe
PE or comorbidities, as ST was administered in case of
persistent or recurrent hemodynamic instability after
USAT or vice versa, indicating a severely high-risk
situation.
The population of patients with high-risk PE is very
heterogeneous, ranging from mildly hypotensive, con-
scious patients to patients in cardiac arrest in which
everything must be brought into play. Current guidelines
aimed at high-risk PE patients should apply to both, while
actual clinical management clearly differs between
patients. Treatment decisions can be particularly difficult,
since time is limited and both PE and bleeding can be life-
threatening. A multidisciplinary approach to discuss
available options (ST, USAT, other catheter-directed or
surgical options) is important. The present study affirms
that, although USAT is thought to be associated with a
lower incidence of bleeding, this type of thrombolysis still
carries an important risk of bleeding and mortality. Further
research involving patients with high-risk PE is warranted
to clarify which patients will benefit most from USAT.
The main strength of the present study is the inclusion of
all patients treated with USAT for high-risk PE in the
Netherlands, with little loss to follow-up. Our study is the
first case series of high-risk patients treated with USAT for
PE. This illustrates how guidelines for high-risk PE are put
to practice. Therefore, our results are generalizable to all
hospitals treating patients according to current guidelines.
In a setting of severe disease such as high-risk PE, results
Table 1 Baseline characteristics
n (% of 33)
Demographic data
Age (median years (IQR)) 63 (51–71)
Female (%) 17 (52)
Patient related factors
History of VTE 8 (25)a
Active malignancy 8 (24)
Therapeutic anticoagulation (VKA, DOAC) 2 (6)
Clinical status
Hypotension (SBP\ 100 mmHg) 18 (62)b
Shock 31 (93)a
RV dysfunction 30 (97)c
Resuscitation 20 (61)
Mechanical ventilation 16 (49)a
Major bleeding risk factors
1 risk factor 13 (39)
2 or more risk factors 1 (3)
Minor bleeding risk factors
1 risk factor 6 (18)
2 or more risk factors 1 (3)
Indication for USAT
Contraindications for ST 23 (70)
Insufficient clinical improvement after ST 6 (18)
Unknown 4 (12)
DOAC direct oral anticoagulants, IQR interquartile range, SBP sys-
tolic blood pressure, USAT ultrasound-facilitated, catheter-directed
local thrombolysis, ST systemic thrombolysis, VKA vitamin K
antagonist
an = 32; bn = 29; cn = 31
Table 2 Outcomes
n (% of 33) 95% CI
Primary outcomes (after 1 month)
Major bleeding 12 (36) 22–53
All-cause mortality 16 (49) 31–66
Secondary outcomes (after 3 months)
All-cause mortality 16 (50)a 34–66
Recurrence of VTE 1 (3)a 1–16
Other outcomes
Hospital length of stay (median days (IQR)) 17 (10–30)b
CI Confidence interval, IQR interquartile range, VTE venous
thrombo-embolism
an = 32; bAssessed in all patients surviving the first month of follow-
up
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from case series are especially important to provide points
of departure to guide patient selection.
Some limitations need to be addressed. First, our study
population was small and heterogeneous. As only a small
proportion of patients with PE has an indication for USAT,
it is infrequently performed, which may limit individual
experience. Treatment indications were heterogeneous, as
decisions were made by the treating team of physicians.
Other potential threats to internal validity are predomi-
nantly due to the retrospective design. Information bias
could be introduced as data is extracted from medical
records. Especially in acute situations, information on
baseline characteristics might have been underreported.
Moreover, even though hemodynamic stability was clearly
defined, misclassification could still have occurred.
Conclusion
Although guidelines advocate the use of USAT in those
with high-risk PE and contraindications for thrombolytic
treatment, especially in this population it is associated with
a very high incidence of major bleeding and mortality. As
the first case series of solely high-risk PE patients treated
with USAT, this study adds important data on outcomes of
this understudied population. Our results illustrate that at
least caution is warranted in critically ill patients with high-
risk PE when considering USAT. Further research in high-
risk patients is essential to establish the place of USAT as
treatment of PE.
Funding This study was not supported by any funding.
Table 3 Major bleeding Major bleeding (as defined by the ISTH23) n
Access site hematoma 4
Intrathoracic bleeding (hemothorax or chest wall after traumatic resuscitation or surgery) 4
Intraabdominal hematoma 3
Mucosal bleeding (nasal) 2
Bleeding from ECMO cannula site 1
Hematoma on lower arm, causing compartment syndrome 1
Hemorrhagic transformation of ischemic stroke 1
Total number of major bleeding episodes in 12 patients with major bleeding 16
ECMO extracorporeal membrane oxygenation, ISTH International Society on Thrombosis and Hae-
mostasis, USAT ultrasound-facilitated, catheter-directed local thrombolysis, VKA vitamin K antagonist,
VTE venous thrombo-embolism
Table 4 Additional therapies in
USAT patients
Patient ST Thrombus aspiration VCF ECMO Major bleeding Mortality
1 Full dose – Yes – – Yes
2 – Yes Yes – – –
3 Full dose Yes – Yes – Yes
4 Low dose Yes – – Yes Yes
5 Loading dose Yes – – – Yes
6 Full dose Yes – – Yes –
7 – Yes – Yes – –
8 – Yes – – Yes –
9 – Yes – – – –
10 Lower dose – – – – Yes
11 Lower dose – – – – Yes
12 Lower dose – – Yes – –
13 Lower dose – – – – –
14 Full dose – – Yes Yes Yes
Total 10 8 2 4
ECMO extracorporeal membrane oxygenation, ST systemic thrombolysis, USAT ultrasound-facilitated,
catheter-directed local thrombolysis, VCF vena cava filter
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